QUICK OVERVIEW

Product Name Liraglutide;
Cas No. 204656-20-2;
Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-ε-(Nα-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH;
Molecular Formula C172H265N43O51;
Molar Mass 3751.202 g/mol;
Purity ≥98%;
Impurity ≤0.5% ;
Storage Temperature 2-8℃;
Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement.

Function: Liraglutide is for the treatment of diabetes type 2.

Mechanism of actions: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and CV death in adults with type 2 diabetes and established CV disease.
It was approved by the FDA on December 23, 2014 and by the European Medicines Agency on January 23, 2015, for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition.

Originator Company: Novo Nordisk

Dosage for finished formulation: 18 mg/3ml

Similar effect peptides: Exenatide, Semaglutide

Generic API process in our company: Liraglutide is one of our main peptide projects, related documents will be submitted to the international FDA.